[Preparation, analysis and anti-anemic action of peroral powders with ferrous oxalate. Ferosol. 2].
Experiments with piglets showed good assimilation and metabolism of iron (II) in antianaemic powder Ferosol-1. In order to improve this drug, manganese, calcium (Ferosol-2, 1 composition) and ascorbic acid (Ferosol-2, 2 composition) were added. Manganese and ascorbic acid stimulate erythropoiesis and being strong reductants stabilize iron (II) on storage and in gastrointestinal tract. Components of Ferosol-2 were identified using colour, precipitation- and extraction tests, as well as paper chromatography and absorption spectroscopy. Quantitative analysis of microelements and ascorbic acid was performed using absorption spectroscopy, extraction photometry and iodometric titration methods. Ferosol-2 proved to be more stable than Ferosol-1. Lichfield and Wilkinson method modificated by Roth was used for detection of acute toxicity of Ferosol-2. A local action was estimated on quine pigs. Iron resorption was on 20 days old piglets. Antianaemic effectiveness of Ferosol-2 was evaluated on newborn piglets watching their weight. Experiments with white mice showed low toxicity of Ferosol-2 (LD50 = 4.3 g/kg, for 1 composition and 4.6 g/kg for 2 composition). It does not irritate mucosa of duodenum and ventriculus. Iron in Ferosol-2 was found to be well assimilated in gastrointestinal tract of piglets, easily gets into blood and joins albumen of plasma. After administration of Ferosol-2 to piglets increased iron concentration in blood serum was observed for 3 hours (1 composition) and 6 hours (2 composition). Experimental data showed increased resorption of iron in Ferosol-2, 2 composition due to ascorbic acid. Components of Ferosol-2 are well assimilated and join erythropoetic processes. Ferosol-2 leads to quicker weight gain as well as significantly higher amount of hemoglobin and red blood cells in piglets.
Nenortiene
Palma
P
Kauno medicinos universitetas, Mickeviciaus 9, 3000 Kaunas. npalma@takas.lt
Sapragoniene
Marija
M
Stankevicius
Antanas
A
Matusevicius
Algimantas Petras
AP
Daunoras
Gintaras
G
D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D001205:Ascorbic Acid / Q000032:analysis; D002118:Calcium / Q000032:analysis; D004906:Erythrocyte Count; D004920:Erythropoiesis; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D006168:Guinea Pigs; D006454:Hemoglobins; D007501:Iron / Q000378:metabolism; D008345:Manganese / Q000032:analysis; D051379:Mice; D010070:Oxalates / Q000008:administration & dosage / Q000627:therapeutic use; D010783:Photometry; D011208:Powders; D013053:Spectrophotometry; D013057:Spectrum Analysis; D013552:Swine; D013997:Time Factors
D005296:Ferrous Compounds; D006454:Hemoglobins; D010070:Oxalates; D011208:Powders; D008345:Manganese; D007501:Iron; D001205:Ascorbic Acid; D002118:Calcium